DALLAS, TX / ACCESSWIRE / August 30, 2017 / Stonegate Capital Partners initiates coverage on Payment Data Systems, Inc. (NASDAQ: PYDS):

COMPANY DESCRIPTION

Payment Data Systems, Inc. (NASDAQ: PYDS), together with its subsidiaries, provides integrated electronic payment processing services to merchants and businesses in the United States. The Company offers various types of automated clearing house (ACH) processing, and credit, prepaid card, and debit card-based processing services. The Company also offers merchant account services for the processing of card-based transactions through the VISA, MasterCard, American Express, Discover, and JCB networks, including online terminal services accessed through a website or retail services, accessed through a physical terminal. Furthermore, the Company creates, manages, and processes prepaid card programs for corporate clients to issue prepaid cards to their customer base or employees and also issues general purpose, reloadable cards to consumers as an alternative to a traditional bank account. Payment Data Systems, Inc. was founded in 1998 and is headquartered in San Antonio, Texas.

SUMMARY

Payment Data Systems is using the cash flow from its core ACH, credit card and debit card processing business to invest in new business opportunities. With a solid balance sheet and positive cash flow, the Company is investing for the long-term, and hopes to continue its growth by:

Operating in niche verticals where it can be a leader in ACH and credit card payment processing
Focusing on delivering a better customer experience compared to larger competitors by offering its customers leading technology platforms and customization. As an example, Payment Data Systems states that it was the first prepaid card integrated with Apple Pay
Enabling organic growth through continued use of its indirect sales model to drive revenue growth
Using its cash flow to fund growth initiatives such as continuously innovating its merchant processing platform
Expanding its ACH banking relationships
Increasing the brand awareness of its Akimbo platform
Supplementing its organic growth by targeting acquisitions of credit card processing portfolios that can provide immediate cash flow
Acquiring companies that have complementary products and services such as the March 2017 announced acquisition of Singular Payments; Singular Payments processed $440M in payments and processed 2.5M transactions in 2016. Should the acquisition close, Payment Data Systems should increase its processed payments by about 15% and its processed transactions by about 20%
Continuing to rely on its balance sheet that shows no debt and has a clean capital structure

We employ a comparison analysis using a Price/Sales framework. The details are on page 5. We have not modeled the pending acquisition of Singular Payments and as such, should the acquisition close, this event would represent upside to our forecast. We note that the Company issued a press release 8/28/17 stating that the transaction is set to close 9/1/17, giving us additional confidence that the acquisition will likely come to fruition in the near-term.

The full report can be accessed by clicking on the following link:

http://stonegateinc.com/reports/PYDS_Initiation_AUG_2017.pdf

About Stonegate Capital Partners

Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high quality investment opportunities.

SOURCE: Stonegate Capital Partners

ReleaseID: 474183

LOS ANGELES, CA / ACCESSWIRE /August 30, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Arconic Inc. (”Arconic” or the ”Company”) (NYSE: ARNC; NYSE American: ARNC-P; NYSE: ARNC-PB) for possible violations of federal securities laws from February 28, 2017 through June 26, 2017, inclusive (the ”Class Period”). Investors who purchased or otherwise acquired Arconic shares during the Class Period should contact the firm before the September 11, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may choose to do nothing and be an absent class member as well.

The Complaint alleges that during the Class Period, Arconic made false and misleading statements, and/or failed to disclose: that the Company knowingly supplied its highly flammable Reynobond PE (polyethylene) cladding panels for use in construction; that this conduct significantly increased the risk of property damage, injury and/or death in buildings constructed with Arconic’s Reynobond PE panels; and that as a result, the Company’s public statements were materially false and misleading at all relevant times. Following this news, Arconic’s stock price fell materially, which caused investors harm according to the lawsuit.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE:Lundin Law PC

ReleaseID: 474217

LOS ANGELES, CA / ACCESSWIRE / August 30, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against DryShips Inc. (”DryShips” or the ”Company”) (NASDAQ: DRYS) for possible violations of federal securities laws from June 8, 2016 through July 12, 2017, inclusive (the ”Class Period”). Investors who purchased or otherwise acquired DryShips shares during the Class Period should contact the firm in advance of the September 12, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the lawsuit, throughout the Class Period, DryShips made materially false and/or misleading statements, and/or failed to disclose: that the Company engaged in a systemic stock-manipulation scheme to artificially inflate its share price; that DryShips’ transactions with Kalani Investments Ltd. were an illegal capital-raising scheme, due partly to Kalani’s failure to register as an underwriter with the SEC; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. Since November 2016, shares of DryShips have fallen in value about 99%, which caused investors harm according to the Complaint.

Lundin Law PC was created by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 474218

LOS ANGELES, CA / ACCESSWIRE / August 30, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Foundation Medicine, Inc. (”Foundation” or the ”Company”) (NASDAQ: FMI) for possible violations of federal securities laws from February 26, 2014 through November 3, 2015, inclusive (the ”Class Period”). Investors who purchased or otherwise acquired Foundation shares during the Class Period should contact the firm prior to the September 26, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Foundation made false and misleading statements, and/or failed to disclose, material information to investors. On July 29, 2015, the Company disclosed that it was not making the strides obtaining coverage it claimed to have been making during the Class Period, and that Foundation would receive no Medicare payments in 2015 for its tumor profiling tests due to a delay in receiving a local coverage determination from its regional Medicare Administrative Contractor. As a result of the delay, the Company cut its 2015 financial guidance, which was based on an assumption that Medicare approval would be obtained in 2015. Following this news, Foundation’s stock price dropped significantly. On November 3, 2015, the Company revealed another revision to the already reduced number of clinical tests it expected to report for 2015. When this news was announced, shares of Foundation fell in value materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 474219

LOS ANGELES, CA / ACCESSWIRE / August 30, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Depomed, Inc. (“Depomed” or the “Company”) (NASDAQ: DEPO) concerning possible violations of federal securities laws between February 26, 2015 and August 7, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Depomed shares during the Class Period should contact the firm prior to the October 17, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Depomed made false and/or misleading statements, and/or failed to disclose: that the Company engaged in questionable practices in connection with the sales and marketing of its opioid products; that this conduct, when it became known, would likely subject Depomed to heightened legal and regulatory scrutiny; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.

On August 7, 2017, Depomed announced that it “recently received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids” and that Depomed had also received “subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.” Upon release of this information, shares of Depomed decreased in value, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 474220

LOS ANGELES, CA / ACCESSWIRE / August 30, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (NASDAQ: OCUL) regarding possible violations of federal securities laws from May 5, 2017 through July 6, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Ocular shares during the Class Period should contact the firm before the September 5, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may choose to do nothing and be an absent class member as well.

According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management misled investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that these manufacturing issues could endanger the approval of DEXTENZA by the FDA; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news went public, shares of Ocular lowered in value materially, which caused investors harm according to the lawsuit.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles, dedicated to upholding shareholders’ rights.

This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 474216

IRVINE, CA / ACCESSWIRE / August 30, 2017 / Khang & Khang LLP (the ”Firm”) announces a securities class action lawsuit against Avinger, Inc. (”Avinger” or the ”Company”) (NASDAQ: AVGR). Investors who purchased or otherwise acquired shares pursuant and/or traceable to the Company’s initial public offering on January 30, 2015 (the ”IPO”), are encouraged to contact the Firm in advance of the September 5, 2017 lead plaintiff motion deadline.

If you purchased Avinger shares on or about the IPO, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, Avinger filed documents in connection with the IPO that contained materially false and misleading statements and/or failed to disclose: that Avinger did not have adequate sales and marketing personnel to increase sales of its lumivascular platform products and to commercialize Pantheris; that the Company already experienced problems with the robustness of its lumivascular platform devices, including Pantheris; that physicians and hospitals were requiring more extensive and comprehensive training and education on the benefits of Avinger’s products to convince them to adopt and implement its lumivascular platform products compared to competing products and procedures available in the market; that Avinger would not be able to achieve a rapid ramp rate for increased sales of its lumivascular platform; and that as a result, the Company was experiencing lower sales and revenues. When this information was released, Avinger’s share price dropped, causing investors harm according to the Complaint. On May 3, 2017, the stock closed at $0.57 per share, a decline of over 95% from the IPO price.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 474215

NEW YORK, NY / ACCESSWIRE / August 30, 2017 / Over the course of the past decade, new and lesser-known vineyards outside of Napa Valley have produced outstanding vintages that have received international acclaim at an unprecedented rate. As California’s viticulture landscape begins to shift dramatically, international wine consultant Steven Zoernack shared his thoughts on the state’s emerging grape regions that will come to define the industry.

A few miles from the Pacific Ocean in southern San Luis Obispo County, the Arroyo Grande and Edna Valleys have become home to some of the west coast’s most championed winemakers. Situated in between steep volcanic peaks, the area is full of wildly varying soils and has a tradition growing Chardonnay that dates back to the early 1970s. The region has grown to be respected for the quality and consistency of its wines. Despite these successes, water scarcity and a handful of big companies who dominated the valleys for many years have made it difficult for emerging winemakers to establish brands that could achieve national acclaim. As the economic environment becomes more favorable to independent growers, local wines are earning spots on wine lists around the world. Combined with a re-energized marketing effort from the San Luis Obispo Wine Country group, Steven Zoernack foresees the Arroyo Grande and Edna Valleys developing considerably in the coming years.

Further south from the Central Coast is Temecula Valley, a region of rolling hills in southern Riverside County where grapes have been grown since the 1960s. In recent years, the wineries here have undergone a collective effort to focus intently on their vineyards and prioritize quality. As a result, they began to produce bottles that are competing against California’s most established regions. Temecula was known for its young, on the rise, independent growers throughout the 1970s and 80s, but took a major setback in the late 1990s when Pierce’s disease decimated the region’s vineyards. Essentially starting anew, the vintners who stayed began replanting with varietals and clones that thrive in the valley’s hot summers and low rainfall. Their dedication is paying off, and in addition to significant improvements in quality, the area is quickly becoming the country’s top destination for wine country outings.

Steven Zoernack attended Boston University’s School of Engineering and Fordham University’s School of Economics at Lincoln Center in New York. After a thirty-year career in the financial services sector, employed by some of the most prestigious investment banks of the times including Lehman Brothers and Bear Stearns, Zoernack opted to follow a lifelong passion and pursue a profession in the agricultural industry as an independent wine consultant, conducting wine tastings and reviews for California’s most prestigious wineries. In the coming years, Zoernack plans to branch into vineyard ownership, management and winemaking, with a focus on organic farming.

Steven Zoernack: http://stevenzoernack.com
Steven Zoernack (@StevenZoernack) – Twitter: https://twitter.com/stevenzoernack
Steven Zoernack – | crunchbase: https://www.crunchbase.com/person/steven-zoernack-2

Contact Information:

StevenZoernack.com
contact@stevenzoernack.com
http://stevenzoernack.com

SOURCE: Steven Zoernack

ReleaseID: 474214

CHICAGO, IL / ACCESSWIRE / August 30, 2017 / Methode Electronics, Inc. (NYSE: MEI) will host a conference call and live webcast to discuss the results of the fiscal 2018 first quarter, to be held Thursday, August 31, 2017 at 11:00 AM Eastern Time.

Live Event Information

To participate, connect approximately 5 to 10 minutes before the beginning of the event.

Date, Time: August 31, 2017 at 11:00 AM ET
Toll Free: 877-407-9210
International: 201-689-8049
Live Webcast: http://www.investorcalendar.com/event/20005 or www.methode.com

Replay Information

The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on October 1, 2017.

Toll Free: 877-481-4010
International: 919-882-2331
Replay ID#: 20005
Webcast: www.investorcalendar.com or www.methode.com

About Methode Electronics, Inc.

Methode Electronics, Inc. (NYSE: MEI) is a global developer of custom engineered and application specific products and solutions with manufacturing, design and testing facilities in China, Egypt, Germany, India, Italy, Lebanon, Malta, Mexico, Singapore, Switzerland, the United Kingdom and the United States. We design, manufacture and market devices employing electrical, electronic, wireless, safety radio remote control, sensing and optical technologies to control and convey signals through sensors, interconnections and controls. Our business is managed on a segment basis, with those segments being Automotive, Interface, Power Products and Other. Our components are in the primary end markets of the automobile, computer, information processing and networking equipment, voice and data communication systems, consumer electronics, appliances, aerospace vehicles and industrial equipment industries. Further information can be found on Methode’s Website at www.methode.com.

SOURCE: Investor Network

ReleaseID: 474211